Dr. Matthew Sirott
“I believe that treatment of the whole patient, as well as the disease, is crucial. While firmly committed to advancing the science of oncology, including cutting-edge research, I also integrate wellness into treatment planning, including diet, exercise, and emotional support. Our new state-of-the-art center easily allows for a comprehensive patient care approach so that we can deliver the very best, compassionate cancer care available.”
Meet Dr. Sirott
Dr. Matthew Sirott was born and raised outside of Philadelphia, Pennsylvania. He graduated from a six-year medical program, receiving his B.A. from Lehigh University and his M.D. from the Medical College of Pennsylvania. After completing a three-year residency in Internal Medicine at Montefiore Medical Center of the Albert Einstein College of Medicine in New York City, he completed his oncology fellowship at Memorial Sloan-Kettering Cancer Center and his hematology training at New York Hospital, Cornell University Medical Center.
At John Muir Medical Center, Dr. Sirott served as the Chairman of the Pharmacy & Therapeutics Committee for twelve years and the Chairman the Cancer Committee and Director of Oncology for fourteen years.
Dr. Sirott has been in private practice in Walnut Creek since 1992. He founded Diablo Valley Oncology and Hematology Medical Group and continues to serve as the President and CEO. Under his leadership in 2008, Diablo Valley Oncology opened the state-of-the-art California Cancer and Research Institute, in which all cancer treatment services can be delivered in one location, greatly simplifying a patient’s course of therapy. Therapies available include chemotherapy and immunotherapy infusion, radiation therapy, diagnostic imaging, research and patient services. Contact us to request an appointment with Dr. Sirott.
Board certified in Internal Medicine and Medical Oncology and board eligible in Hematology
Dr. Sirott has extensive experience in the treatment of all tumor types with a special interest in genitourinary cancers and cancers of the central nervous system.